A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Celiac Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Celiac Disease
- Sponsor
- ProgenaBiome
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Correlation of Microbiome to Celiac Disease via Relative Abundance Found in Microbiome Sequencing
- Status
- Withdrawn
- Last Updated
- 11 months ago
Overview
Brief Summary
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Celiac Disease.
Detailed Description
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding Celiac Disease
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
- •Male or female patients of any age (interest is given to children to compare with mothers).
- •Diagnosis of Celiac Disease
Exclusion Criteria
- •Refusal to sign informed consent form
- •History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
- •Postoperative stoma, ostomy, or ileoanal pouch
- •Participation in any experimental drug protocol within the past 12 weeks
- •Treatment with total parenteral nutrition
- •Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
- •Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
Outcomes
Primary Outcomes
Correlation of Microbiome to Celiac Disease via Relative Abundance Found in Microbiome Sequencing
Time Frame: One year
Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized among specific disease types.
Secondary Outcomes
- Validation of Sequencing Methods(One year)